Robert Renninger - 01 Oct 2024 Form 4 Insider Report for Athira Pharma, Inc. (ATHA)

Role
VP of Finance
Signature
s/ Mark Worthington, Attorney-in-Fact for Robert Renninger
Issuer symbol
ATHA
Transactions as of
01 Oct 2024
Net transactions value
$0
Form type
4
Filing time
03 Oct 2024, 19:17:34 UTC
Next filing
03 Jan 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATHA Restricted Stock Units Award $0 +37,077 $0.000000 37,077 01 Oct 2024 Common Stock 37,077 Direct F1, F2
transaction ATHA Stock Option (Right to Buy) Award $0 +37,077 $0.000000 37,077 01 Oct 2024 Common Stock 37,077 $0.4499 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of Issuer's common stock.
F2 One-third (1/3rd) of the RSUs shall vest on each of December 31, 2024, June 30, 2025 and December 31, 2025, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan (the "Plan")) through the applicable vesting dates.
F3 One-third (1/3rd) of the shares subject to the option shall vest on each of December 31, 2024, June 30, 2025 and December 31, 2025, subject to the Reporting Person continuing to be a Service Provider through the applicable vesting dates.